PD-L1 Polyclonal Antibody

Price:
- 宿主: Rabbit
- 反应性: Human;Mouse;Rat
- 应用性: IF
Verified Samples |
Verified Samples in IF: RAW264.7 |
Dilution | IF 1:50-1:200 |
Clonality | Polyclonal |
Isotype | IgG |
Immunogen | Recombinant fusion protein of human PD-L1 (NP_054862.1). |
Abbre | PD-L1 |
Synonyms | B7-H, B7H1, CD274, PD-L1, PDCD1L1, PDCD1LG1, PDL1 |
Swissprot | |
Cellular Localization | Cell membrane and Endomembrane system. |
Concentration | 1 mg/mL |
Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
Buffer | PBS with 0.02% sodium azide, 50% glycerol, pH 7.3. |
Purification Method | Affinity purification |
Research Areas | Cancer, Immunology |
Conjugation | Unconjugated |
Background | This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. |
-
The expression and significance of PD‐L1 in condyloma acuminatum
IF: 2.200 -
A Trojan Horse Delivery Vehicle Carrying siRNA Nanotherapeutics with Multiple Tumor Microenvironment Responsiveness Elicits Robust Antitumor Immune Responses In Situ via a “Self-Synergistic” Approach
IF: 10.000 -
O-carboxymethyl chitosan based pH/hypoxia-responsive micelles relieve hypoxia and induce ROS in tumor microenvironment
IF: 9.381